Coferon Inc. is using a bioorthogonal linker technology to deliver two halves of a therapeutic that self-assemble on the target after gaining entry into a cell. The company announced the close of a $12 million series B round. Coferon's technology involves splitting a therapeutic into two smaller components that can cross the cell membrane and then reassemble inside the cell. The company is focusing on autoimmune, cancer, and infectious diseases, with ongoing discovery projects targeting BRD4 and an undisclosed infectious disease target. Coferon aims to partner for the bromodomain project and advance the infectious disease program through Phase II testing.
documents/EFTA01092526.pdf
{}